First-Line Triplet in BRAF+ mCRC

Video

An overview of the goals and design of the phase II single arm ANCHOR trial, which looks at the combination triplet regimen used in the BEACON study, encorafenib, binimetinib, and cetuximab, as first-line treatment for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Related Videos
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
Scott Kopetz, MD, PhD, FACP
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Pashtoon Murtaza Kasi, MD, MS
Related Content
Guido Baechler

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
Heinz-Josef Lenz, MD, University of Southern California Norris Comprehensive Cancer Center

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
FDA

FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

April 23rd 2024
Article
Subcutaneous Atezolizumab in Cancer: © vxnaghiyev - stock.adobe.com

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024
Article